Othera Pharmaceuticals Reports Preserved Visual Function in Clinical Trial of OT-551 Eye Drop Treatment for Advanced Dry AMD
3/23/2010 12:45:58 PM
WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc., a specialty pharmaceutical company focused on treatments for ophthalmic diseases, today announced positive visual function results from a Phase I/II trial of OT-551 conducted at the National Eye Institute (NEI) of the National Institutes of Health (NIH) in patients with bilateral geographic atrophy, an advanced form of dry age-related macular degeneration (dry AMD). Results of this study will be the subject of a poster presentation as part of the “Late Breaking Posters” section at the Association for Research in Vision and Ophthalmology (ARVO) 2010 Annual Meeting, to be held May 2 – 6 in Fort Lauderdale, Florida. A second poster will also present incomplete results from the OMEGA Phase II trial of OT-551, which enrolled a different patient population and employed a different dosing regimen than the NEI study.